iShares MSCI Hong Kong ETF vs Liquidia Corporation Common Stock — how do they compare? iShares MSCI Hong Kong ETF trades at $21.92 (market cap $1.21B), while Liquidia Corporation Common Stock trades at $34.27 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is far larger — about 2.5× iShares MSCI Hong Kong ETF's market cap, and Liquidia Corporation Common Stock is more actively traded (21,111,778 versus 9,334,618). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 63 Days and Liquidia Corporation Common Stock for 0 Days on average.
| EWH | LQDA | |
|---|---|---|
Market Cap | $1.21B | $3.04B |
Volume | 9,334,618 | 21,111,778 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $91.03 |
52-Week Low | $20.92 | $22.02 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $2.94B |
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.35 with a 1.78% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster tightly around $22.
The outlook remains cautious given Hong Kong's market volatility and geopolitical risks. Investment opportunity exists for contrarian bets on Chinese tech recovery, but risks include sustained Fed tightening and regional tensions. Wall Street sentiment is divided, with some seeing value in oversold conditions while others warn of further downside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →